Na+ CP type III Inhibitors
Chemical inhibitors of Na+ CP type III can effectively alter the protein's function by targeting the epithelial sodium channels (ENaC) that are crucial for its operation. Amiloride, a well-known ENaC blocker, binds to the sodium channels, resulting in a reduced absorption of sodium ions across the epithelial cells where these channels are prevalent. This leads to a lower transepithelial potential difference, thus decreasing the driving force for sodium uptake that Na+ CP type III depends on. Similarly, Benzamil and Phenamil, both analogs of Amiloride, specifically inhibit these channels, diminishing the sodium gradient necessary for the protein's activity. By obstructing the sodium influx, these inhibitors directly impact the functionality of Na+ CP type III.
Hexamethylene amiloride, a more potent derivative of amiloride, along with Ethylisopropylamiloride and Dimethylamiloride, also targets ENaC channels, reducing sodium reabsorption and consequently altering the sodium gradient that Na+ CP type III utilizes for sodium transport. Pyrazinoylguanidine adds to this list by inhibiting sodium channels and disrupting the sodium balance across the cell membrane, which is vital for the operation of Na+ CP type III. Triamterene, through its diuretic action, inhibits sodium reabsorption at the distal renal tubules by blocking ENaC, which in turn influences Na+ CP type III activity. Additionally, Tertiapin-Q, though selectively targeting certain potassium channels, has been found to inhibit ENaC as well, which can indirectly decrease the activity of Na+ CP type III by altering ionic gradients and electrical signaling pathways. Spironolactone, by antagonizing aldosterone, indirectly affects ENaC channel protein synthesis, which has downstream effects on Na+ CP type III function by modifying its driving sodium gradient.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Amiloride | 2609-46-3 | sc-337527 | 1 g | $296.00 | 7 | |
Amiloride selectively inhibits epithelial sodium channels (ENaC), which are a component of the Na+ CP type III system, leading to decreased sodium reabsorption in tissues where these channels are present. This inhibition lowers the transepithelial potential difference, which can decrease the driving force for sodium uptake through Na+ CP type III. | ||||||
Benzamil•HCl | 161804-20-2 | sc-201070 | 50 mg | $195.00 | 1 | |
Benzamil is an amiloride analog that also specifically inhibits ENaC channels. Its binding to the channel leads to a decrease in sodium transport across the epithelium, thereby functionally inhibiting the activity of Na+ CP type III by reducing the electrochemical gradient necessary for its operation. | ||||||
Triamterene | 396-01-0 | sc-213103A sc-213103 | 1 g 5 g | $22.00 $54.00 | ||
Triamterene serves as a potassium-sparing diuretic that inhibits sodium reabsorption at the distal renal tubules via ENaC blockade. By inhibiting these channels, Triamterene effectively reduces the sodium gradient that Na+ CP type III relies on for its function, resulting in its inhibition. | ||||||
5-(N,N-Hexamethylene)amiloride | 1428-95-1 | sc-239021 | 25 mg | $100.00 | 2 | |
Hexamethylene amiloride is a derivative of amiloride with a more potent inhibitory effect on ENaC. Its action on these channels leads to a decreased sodium reabsorption, which directly impacts the activity of Na+ CP type III by altering the sodium gradient that is essential for its function. | ||||||
5-(N-Ethyl-N-isopropyl)-Amiloride | 1154-25-2 | sc-202458 | 5 mg | $104.00 | 20 | |
Ethylisopropylamiloride is a compound that inhibits ENaC channels, reducing sodium uptake. This inhibition lowers the sodium gradient across epithelial cells, which in turn inhibits the Na+ CP type III due to its reliance on this gradient for proper function. | ||||||
Amiloride, 5-(N,N-Dimethyl)-, hydrochloride | 2235-97-4 | sc-202459 | 5 mg | $235.00 | 7 | |
Dimethylamiloride is a modified form of amiloride which acts to inhibit ENaC channels, thus reducing sodium reabsorption and disrupting the electrochemical gradient. This reduction in the sodium gradient can inhibit the activity of Na+ CP type III as it depends on this gradient for its sodium transport function. | ||||||
Spironolactone | 52-01-7 | sc-204294 | 50 mg | $109.00 | 3 | |
Spironolactone is an aldosterone antagonist that indirectly inhibits ENaC channels by preventing aldosterone from inducing the transcription of genes encoding for ENaC subunits. | ||||||